Many medicines are harmful to the liver, and drug-induced liver injury (DILI) now ranks as the leading cause of liver failure and transplantation in western countries. However, predicting which drugs will prove toxic to the liver is extremely difficult, and often problems are not detected until a drug is already on the market. For the first time, the IMI project MIP-DILI brings together Europe’s top industrial and academic experts in the field. Together, they will develop new tests that will help researchers detect potential liver toxicity issues much earlier in development, saving many patients from the trauma of liver failure.
Clinicians and drug manufacturers recognise two kinds of DILI. Dose-dependent DILI is usually detected early on in drug development and, as the name suggests, the risk of an adverse reaction increases with the dosage. However, most DILIs are so-called idiosyncratic reactions. These cannot be predicted in experimental systems, occur only in certain patients, and are not dose dependent. Very often, idiosyncratic DILI problems are only picked up very late in drug development or even after regulatory approval. Over 1 000 approved drugs have been associated with idiosyncratic DILI; in most cases, around 1 in 10 000 patients are affected, although for some drugs the incidence of DILI is higher, at around 1 patient in 100. Estimates suggest that one in seven cases of liver failure are triggered by an adverse drug reaction, and DILI is now the leading cause of liver transplantation in many countries.
A new look at liver toxicity
The goal of MIP-DILI is to dramatically improve the tools used to test for liver toxicity during drug development. The team aims to deepen our understanding of the science behind drug-induced liver injury, and use that knowledge to overcome the many drawbacks of the tests currently used.
A major focus will be on a systematic and evidence-based evaluation of both currently available and new laboratory test systems, including cultures of liver cells in one-dimensional and three dimensional configurations. The more complex models integrate different types of liver cells to form three-dimensional units that accurately mimic human liver physiology. The project will also develop models that take into account the natural differences between patients. This is important because factors such as certain genes, the liver’s immune response, and viral infections have all been associated with an increased risk of DILI.
The project will seek to address the current lack of human liver cells available to researchers by using induced pluripotent stem cells (iPSCs, i.e. cells that have been altered so that they can turn into any kind of cell found in the body) generated from patients who are particularly sensitive to DILI.
Another strand of the project will develop computer models to unravel the complex, often inter-related mechanisms behind DILI. Finally, the team will assess how accurate the results of laboratory tests are at predicting actual outcomes in patients.
A leap forward for liver safety
Until now, the quest to develop better tests for DILI risk in potential drugs has been hampered by a lack of collaboration between industry and academia. By bringing together experts from these sectors in a single, coordinated effort, MIP-DILI promises to both advance our understanding of drug-induced liver injury and deliver tests to detect it early on in drug development.
Academic partners in the project will benefit from access to reference compounds, with known liver toxicity, that are held by pharmaceutical companies. For their part, pharmaceutical companies will gain a greater understanding of the complex science behind DILI.
The stakes are high; all too often, DILI and other toxicity problems are only identified extremely late in drug development, when vast amounts of time and money have been spent on a potential drug. According to a report from the Society for Medicines Research, just a 10% improvement in predicting failure before the start of clinical trials could cut the costs of drug development by upwards of €75 million.
Safer treatments for patients
Although DILI is rare, when it happens, it is often extremely serious or even fatal for the patient concerned. Yet too many drugs that pose a risk of DILI still make it to the market, and DILI is a common reason for withdrawing drugs from the market. By helping researchers to detect DILI problems during drug research, before drugs are evaluated in clinical trials and approved for use, MIP-DILI will prevent considerable pain and suffering on the part of patients.
- AstraZeneca AB, Södertälje, Sweden
- Abbott GmbH & CoKG, Wiesbaden-Delkenheim, Germany
- Bristol Myers Squibb EMEA sarl, New York, US
- GlaxoSmithKline Research and Development Ltd, Middlesex, UK
- H. Lundbeck A/S, Valby, Denmark
- Institut de Recherches Internationales Servier, Suresnes, France
- Janssen Pharmaceutica NV, Beerse, Belgium
- Merck KGaA, Darmstadt, Germany
- Orion Corporation, Espoo, Finland
- Sanofi-Aventis Research and Development, Chilly-Mazarin, France
- UCB Pharma SA, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
- University of Liverpool, Liverpool, UK
- Albert-Ludwigs-University Freiburg, Freiburg, Germany
- Deutsches Krebsforschungszentrum, Heidelberg, Germany
- Karolinska Institutet, Stockholm, Sweden
- Universitätsklinikum Bonn, Bonn, Germany
- Université de Rennes 1, Rennes, France
- Universiteit Leiden, Leiden, the Netherlands
- Universiteit Utrecht, Utrecht, the Netherlands
- Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg, Amsterdam, the Netherlands
- Cellartis AB, Gothenburg, Sweden
- CXR Biosciences Ltd., Dundee, UK
- Interface Europe, Brussels, Belgium
- KaLy-Cell, Illkirch, France
- Lhasa Ltd., Leeds, UK
- Solvo Biotechnology ZRT, Szeged, Hungary
Facts & Figures
|IMI funding||15 300 000|
|EFPIA in kind||11 000 000|
|EFPIA US||1 600 000|
|Other||4 500 000|
|Total cost||32 400 000|
Tel: +32 2 2130030